PL2726507T3 - Przeciwciała przeciwko antygenowi komórek macierzystych swoistemu dla gruczołu krokowego i ich zastosowanie - Google Patents

Przeciwciała przeciwko antygenowi komórek macierzystych swoistemu dla gruczołu krokowego i ich zastosowanie

Info

Publication number
PL2726507T3
PL2726507T3 PL12729996T PL12729996T PL2726507T3 PL 2726507 T3 PL2726507 T3 PL 2726507T3 PL 12729996 T PL12729996 T PL 12729996T PL 12729996 T PL12729996 T PL 12729996T PL 2726507 T3 PL2726507 T3 PL 2726507T3
Authority
PL
Poland
Prior art keywords
stem cell
antibodies against
cell antigen
specific stem
against prostate
Prior art date
Application number
PL12729996T
Other languages
English (en)
Polish (pl)
Inventor
Michael Bachmann
Original Assignee
Gemoab Monoclonals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemoab Monoclonals Gmbh filed Critical Gemoab Monoclonals Gmbh
Publication of PL2726507T3 publication Critical patent/PL2726507T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL12729996T 2011-06-30 2012-06-29 Przeciwciała przeciwko antygenowi komórek macierzystych swoistemu dla gruczołu krokowego i ich zastosowanie PL2726507T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
PCT/EP2012/062716 WO2013001065A1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
EP12729996.4A EP2726507B1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung

Publications (1)

Publication Number Publication Date
PL2726507T3 true PL2726507T3 (pl) 2019-06-28

Family

ID=46384405

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12729996T PL2726507T3 (pl) 2011-06-30 2012-06-29 Przeciwciała przeciwko antygenowi komórek macierzystych swoistemu dla gruczołu krokowego i ich zastosowanie

Country Status (18)

Country Link
US (1) US9200078B2 (enExample)
EP (2) EP3505536B1 (enExample)
JP (4) JP2014528696A (enExample)
AU (1) AU2012277784B2 (enExample)
CY (1) CY1121249T1 (enExample)
DE (1) DE102011118022B4 (enExample)
DK (1) DK2726507T3 (enExample)
ES (2) ES2711978T3 (enExample)
HR (1) HRP20190289T1 (enExample)
HU (1) HUE042008T2 (enExample)
LT (1) LT2726507T (enExample)
PL (1) PL2726507T3 (enExample)
PT (1) PT2726507T (enExample)
RS (1) RS58448B1 (enExample)
SI (1) SI2726507T1 (enExample)
SM (1) SMT201900085T1 (enExample)
TR (1) TR201901991T4 (enExample)
WO (1) WO2013001065A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
KR20190118172A (ko) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
WO2019157366A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008684A (es) 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
AU2021276327A1 (en) * 2020-05-19 2022-12-01 City Of Hope Engineered anti-prostate stem cell antigen fusion proteins and uses thereof
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
CA2281877C (en) * 1997-03-10 2010-01-05 The Regents Of The University Of California Psca: prostate stem cell antigen
CA2387108A1 (en) * 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
DK1673398T3 (da) * 2003-10-16 2011-04-18 Micromet Ag Multispecifikke, deimmuniserede CD3-bindere
MXPA06013834A (es) * 2004-05-28 2007-03-01 Agensys Inc Anticuerpos y moleculas relacionadas que enlazan a proteinas psca.
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
SG194399A1 (en) * 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations
DE102011118022B4 (de) 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Also Published As

Publication number Publication date
AU2012277784A1 (en) 2014-02-06
DE102011118022B4 (de) 2018-01-18
TR201901991T4 (tr) 2019-03-21
RS58448B1 (sr) 2019-04-30
PT2726507T (pt) 2019-02-26
ES2711978T3 (es) 2019-05-08
EP2726507A1 (de) 2014-05-07
JP2021121201A (ja) 2021-08-26
HUE042008T2 (hu) 2019-06-28
DE102011118022A1 (de) 2013-01-03
SI2726507T1 (sl) 2019-05-31
EP3505536A1 (de) 2019-07-03
HRP20190289T1 (hr) 2019-05-03
EP3505536B1 (de) 2024-08-07
JP7341185B2 (ja) 2023-09-08
LT2726507T (lt) 2019-04-10
AU2012277784B2 (en) 2015-08-20
JP2019193652A (ja) 2019-11-07
US9200078B2 (en) 2015-12-01
DK2726507T3 (en) 2019-03-11
CY1121249T1 (el) 2020-05-29
WO2013001065A1 (de) 2013-01-03
JP2014528696A (ja) 2014-10-30
SMT201900085T1 (it) 2019-05-10
EP3505536C0 (de) 2024-08-07
US20140134155A1 (en) 2014-05-15
JP2017104113A (ja) 2017-06-15
EP2726507B1 (de) 2018-11-21
JP6886491B2 (ja) 2021-06-16
JP6549622B2 (ja) 2019-07-24
ES2989975T3 (es) 2024-11-28

Similar Documents

Publication Publication Date Title
IL288203B (en) Meditops and Meditop binding antibodies and their use
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
PL2726507T3 (pl) Przeciwciała przeciwko antygenowi komórek macierzystych swoistemu dla gruczołu krokowego i ich zastosowanie
IL259436A (en) Antibodies against 3angptl and their uses
IL251697A0 (en) Antibodies against 3erbb and their uses
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
ZA201403264B (en) Neutralizing gp41 antibodies and their use
GB201115529D0 (en) Antibodies, uses and methods
GB201115280D0 (en) Antibodies, uses and methods
IL232213B (en) Antibody Formulations and Methods
PT2729170T (pt) Variantes de anticorpos e utilizações das mesmas